The experimental coronavirus treatment remdesivir has shortened the recovery time for COVID-19 patients, according to data from a new study cited by the U.S. government. The study was run by National Institutes of Health [NIH] and tested remdesivir versus usual care in 1,063 hospitalized coronavirus patients around the world. Earlier on Wednesday Gilead said that remdesivir generated “positive data” in a trial of the antiviral organized by the National Institute of Allergy and Infectious Diseases (NIAID). EXPERIMENTAL CORONAVIRUS TREATMENT REMDESIVIR DELIVERS 'POSITIVE DATA' IN TRIAL, SAYS DEVELOPER GILEADDuring his press conference, Fauci said that more information on remdesivir’s performance will be forthcoming. EXPERIMENTAL CORONAVIRUS DRUG REMDESIVIR IS SHOWING EARLY PROMISE, RESEARCH SAYSIn the U.S., remdesivir is still awaiting regulatory approval as a coronavirus treatment.

Source: Fox News April 29, 2020 21:00 UTC